Nhwd-870
Advanced Solid Tumors or Lymphomas
Hunan Province Tumor HospitalActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Advanced Solid Tumors or Lymphomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CA 170 Curis, Inc. | Phase 1 | CC |
js019 Suzhou Kebo Ruijun Biotechnology Co., Ltd | Phase 1 | CC |
Same molecule, other indications
Nhwd-870 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →